Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001558370-22-013275
Filing Date
2022-08-11
Accepted
2022-08-11 16:08:08
Documents
88
Period of Report
2022-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q fbio-20220630x10q.htm   iXBRL 10-Q 3593951
2 EX-31.1 fbio-20220630xex31d1.htm EX-31.1 13871
3 EX-31.2 fbio-20220630xex31d2.htm EX-31.2 14573
4 EX-32.1 fbio-20220630xex32d1.htm EX-32.1 8233
5 EX-32.2 fbio-20220630xex32d2.htm EX-32.2 8189
  Complete submission text file 0001558370-22-013275.txt   12703506

Data Files

Seq Description Document Type Size
6 EX-101.SCH fbio-20220630.xsd EX-101.SCH 84590
7 EX-101.CAL fbio-20220630_cal.xml EX-101.CAL 88220
8 EX-101.DEF fbio-20220630_def.xml EX-101.DEF 317941
9 EX-101.LAB fbio-20220630_lab.xml EX-101.LAB 620846
10 EX-101.PRE fbio-20220630_pre.xml EX-101.PRE 509948
82 EXTRACTED XBRL INSTANCE DOCUMENT fbio-20220630x10q_htm.xml XML 2503964
Mailing Address 1111 KANE CONCOURSE SUITE 301 BAY HARBOR ISLANDS FL 33154
Business Address 1111 KANE CONCOURSE SUITE 301 BAY HARBOR ISLANDS FL 33154 781-652-4500
Fortress Biotech, Inc. (Filer) CIK: 0001429260 (see all company filings)

EIN.: 205157386 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-35366 | Film No.: 221155753
SIC: 2834 Pharmaceutical Preparations